A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.
Phase 2
Completed
- Conditions
- Colorectal Cancer
- Registration Number
- NCT00034619
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
The purpose of this study is to assess the antitumor activity of ALIMTA plus Oxaliplatin combination therapy in patients with previously untreated advanced colorectal cancer
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Diagnosis of primary cancer of the colon or rectum
- Must have measurable disease
- Must be able to comply with study procedure
Exclusion Criteria
- Prior chemotherapy for advanced disease
- Pregnancy or lactation
- Candidates for surgical resection of one or more metastatic foci
- Second primary cancer
- Inability to take folic acid or vitamin B12
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
🇺🇸Spokane, Washington, United States